iDNA Genomics Public (CYS:IDNA) Current Deferred Revenue: €0.00 Mil (As of . 20)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CYS:IDNA iDNA Genomics Public Ltd CYS:IDNA
23 GF Score
Price €16.40
! 2 Warning Signs
View Full Analysis

What is iDNA Genomics Public Current Deferred Revenue?

iDNA Genomics Public CYS:IDNA 23 Current Deferred Revenue is €0.00 Mil as of . 20. GuruFocus rates CYS:IDNA with a GF Score™ of 23/100. The stock has 2 warning signs investors should review.

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

iDNA Genomics Public's current deferred revenue for the quarter that ended in . 20 was €0.00 Mil.

iDNA Genomics Public Current Deferred Revenue Related Terms

iDNA Genomics Public Current Deferred Revenue Historical Data

* Premium members only.

The historical data trend for iDNA Genomics Public's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

iDNA Genomics Public Current Deferred Revenue Chart

iDNA Genomics Public Annual Data
Trend
Current Deferred Revenue

iDNA Genomics Public Semi-Annual Data
Current Deferred Revenue
CYS:IDNA
23GF Score
iDNA Genomics Public Ltd CYS:IDNA
Current Deferred Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Current Deferred Revenue of €0.00 Mil mean?
iDNA Genomics Public (CYS:IDNA) has a Current Deferred Revenue of €0.00 Mil as of . 20. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on iDNA Genomics Public and its competitors.
Is iDNA Genomics Public's Current Deferred Revenue too high?
iDNA Genomics Public's current Current Deferred Revenue is €0.00 Mil. Overall, iDNA Genomics Public has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does iDNA Genomics Public's Current Deferred Revenue compare to ?
iDNA Genomics Public's Current Deferred Revenue of €0.00 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Deferred Revenue for a Medical Diagnostics & Research company?
A good Current Deferred Revenue depends on the Medical Diagnostics & Research industry context. However, Current Deferred Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Deferred Revenue mean?
A high Current Deferred Revenue can signal that a stock is expensive relative to its fundamentals. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on iDNA Genomics Public and its competitors. iDNA Genomics Public's current Current Deferred Revenue is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is iDNA Genomics Public stock overvalued right now?
iDNA Genomics Public (CYS:IDNA) has a current Current Deferred Revenue of €0.00 Mil. The current Current Deferred Revenue is €0.00 Mil. iDNA Genomics Public's overall GF Score™ is 23/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Deferred Revenue calculated?
Current Deferred Revenue is calculated from a company's financial statements. For iDNA Genomics Public (CYS:IDNA), the current Current Deferred Revenue is €0.00 Mil as of . 20. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

iDNA Genomics Public Business Description

Comparable Companies
Address 7 Hatzidaki Street, Trypiotis, Nicosia, CYP, 1066
iDNA Genomics Public Ltd operates in the field of genomics and biotechnology and specializes in personalized health care. Its purpose is to develop and provide genetic tests in the field of genomics, through professionals (Medical Genomics) and directly to the consumer (Direct-to-Consumer Genomics).
23GF Score

Get the complete analysis for CYS:IDNA

Current Deferred Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€16.40
Price